ATAI Life Sciences N.V (ATAI) concluded trading on Wednesday at a closing price of $2.47, with 3.93 million shares of worth about $9.7 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.76% during that period and on June 04, 2025 the price saw a gain of about 5.11%. Currently the company’s common shares owned by public are about 199.78M shares, out of which, 136.80M shares are available for trading.
Stock saw a price change of 6.93% in past 5 days and over the past one month there was a price change of 68.03%. Year-to-date (YTD), ATAI shares are showing a performance of 85.71% which increased to 57.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.03 but also hit the highest price of $2.64 during that period. The average intraday trading volume for ATAI Life Sciences N.V shares is 1.95 million. The stock is currently trading 29.73% above its 20-day simple moving average (SMA20), while that difference is up 53.62% for SMA50 and it goes to 65.98% higher than SMA200.
ATAI Life Sciences N.V (NASDAQ: ATAI) currently have 199.78M outstanding shares and institutions hold larger chunk of about 9.95% of that.
The stock has a current market capitalization of $494.83M and its 3Y-monthly beta is at 1.48. It has posted earnings per share of -$0.80 in the same period. It has Quick Ratio of 4.07 while making debt-to-equity ratio of 0.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATAI, volatility over the week remained 5.92% while standing at 5.27% over the month.
Analysts are in expectations that ATAI Life Sciences N.V (ATAI) stock would likely to be making an EPS of -0.11 in the current quarter, while forecast for next quarter EPS is -0.11 and it is -0.71 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.13 which is -0.09 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.36 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 39.07% while it is estimated to decrease by -10.51% in next year. EPS is likely to grow at an annualized rate of 29.20% for next 5-years, compared to annual growth of 18.62% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 18, 2024 offering a Buy rating for the stock and assigned a target price range of between $15 and $10 to it. Coverage by Maxim Group stated ATAI Life Sciences N.V (ATAI) stock as a Buy in their note to investors on April 03, 2024, suggesting a price target of $6 for the stock. On November 01, 2022, Loop Capital Initiated their recommendations, while on November 30, 2021, Maxim Group Initiated their ratings for the stock with a price target of $25. Stock get a Buy rating from ROTH Capital on November 11, 2021.
